Emyria Ltd has released a press release.
First dosing commenced for pivotal EMD-RX5 Phase 3 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Emyria receives $2.1M R&D tax incentive refund
- Emyria accepted into National Institutes of Health Program
- Placement completion and secondary trading notice
- Emyria completes $3m placement
- Emyria and UWA expand unique MDMA-inspired analogue library
Later from Emyria
- Appendix 4C - Quarterly
- Emyria welcomes dosing of first patient in Phase 3 anxiety trial
- Emyria expands MDMA programs following landmark TGA decision
- Emyria ramps up MDMA programs following ‘incredible’ TGA decision
- Emyria secures clinical-grade MDMA supply for Aust patients
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria